Boustani, M., Fox, C., Richardson, K., Sawa, G.M., Smithard, D., Coulton, Simon, Katona, C., Maidment, I., Brayne, C. (2011) Anticholinergics Exposure and the Risk of Cognitive Decline. In: Journal of the American Geriatrics Society. 59 (S1). S68-S69. Blackwell Publishing (doi:10.1111/j.1532-5415.2011.03416.x) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:42680)
The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. | |
Official URL: http://dx.doi.org/10.1111/j.1532-5415.2011.03416.x |
Abstract
BACKGROUND: The role of modifiable risk factors for patients
with dementia and at risk of dementia requires investigation
with large population studies.
OBJECTIVES: To examine the association between anticholinergic
medication use and cognitive decline in the older population
DESIGN: A two-year longitudinal study of participants enrolled
in the Medical Research Council (MRC) Cognitive Function
and Ageing Study (CFAS) between 1991 and 1993.
SETTING: Community and institionalized participants.
PARTICIPANTS: A sample of 13,004 participants aged 65 years
and older.
MEASUREMENTS: Baseline use of possible or definite anticholinergics
as determined by the Anticholinergic Cognitive Burden
(ACB) scale, and cognition as determined by the Mini-Mental State
Examination (MMSE). The main outcome measure was decline on
the mini-mental state examination at 2 years.
RESULTS: At baseline, 47% of the population used a medication
with possible anticholinergic properties and 4% used a drug with
definite anticholinergic properties. After adjusting for age, sex, educational
level, social class, number of non-anticholinergic medications,
number of co-morbid health conditions and cognitive performance at
baseline, the use of medication with definite anticholinergic effects
was associated with an additional reduction in MMSE score of 0.43
points (95% CI 0.11, 0.75; p<0.008) compared to those not taking anticholinergics,
whereas the use of possible anticholinergics at baseline
was not associated with further MMSE decline (estimate=0.00 95%
CI -0.11, 0.11; p=0.98). Two year mortality was increased both for
those taking definite anticholinergic medications (OR 1.68; 95% CI
1.30, 2.16; p<0.001) and for those taking possible anticholinergic medications
(OR 1.56; 95% CI: 1.36, 1.79; p<0.001).
CONCLUSION: The benefits of prescribing definite anticholinergics
may lead to unintended negative consequences on both cognitive
function and mortality among the older population.
Item Type: | Conference or workshop item (Paper) |
---|---|
DOI/Identification number: | 10.1111/j.1532-5415.2011.03416.x |
Subjects: |
R Medicine > RC Internal medicine > RC321 Neuroscience. Biological psychiatry. Neuropsychiatry R Medicine > RC Internal medicine > RC952 Geriatrics |
Divisions: | Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research > Centre for Health Services Studies |
Depositing User: | Simon Coulton |
Date Deposited: | 26 Aug 2014 12:55 UTC |
Last Modified: | 16 Nov 2021 10:16 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/42680 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):